599 related articles for article (PubMed ID: 18953493)
1. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Kang TY; Jin T; Elinzano H; Peereboom D
J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
5. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Omuro AM; Delattre JY
Curr Opin Neurol; 2008 Dec; 21(6):717-9. PubMed ID: 18989118
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Taillibert S; Vincent LA; Granger B; Marie Y; Carpentier C; Guillevin R; Bellanger A; Mokhtari K; Rousseau A; Psimaras D; Dehais C; Sierra del Rio M; Meng Y; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
Neurology; 2009 May; 72(18):1601-6. PubMed ID: 19414728
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
Sahebjam S; Garoufalis E; Guiot MC; Muanza T; Del Maestro R; Petrecca K; Sharma R; Kavan P
Can J Neurol Sci; 2013 Mar; 40(2):241-6. PubMed ID: 23419575
[TBL] [Abstract][Full Text] [Related]
10. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Bokstein F; Shpigel S; Blumenthal DT
Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
[TBL] [Abstract][Full Text] [Related]
11. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
Parekh C; Jubran R; Erdreich-Epstein A; Panigrahy A; Bluml S; Finlay J; Dhall G
J Neurooncol; 2011 Jul; 103(3):673-80. PubMed ID: 21038110
[TBL] [Abstract][Full Text] [Related]
12. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B
Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358
[TBL] [Abstract][Full Text] [Related]
13. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Tabouret E; Barrie M; Thiebaut A; Matta M; Boucard C; Autran D; Loundou A; Chinot O
J Neurooncol; 2013 Sep; 114(2):191-8. PubMed ID: 23756726
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
[TBL] [Abstract][Full Text] [Related]
15. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
Zhang W; Qiu XG; Chen BS; Li SW; Cui Y; Ren H; Jiang T
Chin Med J (Engl); 2009 Jun; 122(11):1250-4. PubMed ID: 19567132
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
